Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

ACTIVE NOT RECRUITING

Identifier: CI-TRIAL-00115392
Entity page: /trial/NCT05455697 ↗
Edges: 10

Neighbours: 3 cancers7 drugs
Drawn: 10 of 10 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma condition of …CONDITION_OFderived3 of 3
← condition of	Diffuse Large B-Cell Lymphoma registry condition “Diffuse Large B-Cell Lymphoma” mapped CURATED_BROADER	—	—	Diffuse Large B-Cell Lymphoma	1	Observed	clinicaltrials	graph →
← condition of	Grade 3b Follicular Lymphoma registry condition “Grade 3b Follicular Lymphoma” mapped ONTOLOGY_EXACT

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma intervention of …INTERVENTION_OFderived7 of 7
← intervention of	Cyclophosphamidesmall molecule registry intervention “Cyclophosphamide” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Doxorubicinsmall molecule registry intervention “Doxorubicin” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Polatuzumab Vedotinadc registry intervention “Polatuzumab Vedotin” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Prednisonesmall molecule registry intervention “Prednisone” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Retifanlimabmonoclonal antibody registry intervention “Retifanlimab” (BIOLOGICAL) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Tafasitamabmonoclonal antibody registry intervention “Tafasitamab” (BIOLOGICAL) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Vincristinesmall molecule registry intervention “Vincristine” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma intervention of …INTERVENTION_OFderived7 of 7

← intervention of

Cyclophosphamidesmall molecule

registry intervention “Cyclophosphamide” (DRUG) mapped ALIAS

—

not mapped

Observed

clinicaltrials

graph →

← intervention of

Doxorubicinsmall molecule

registry intervention “Doxorubicin” (DRUG) mapped ALIAS

—